专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08168410B2 Anti-IGF-IR antibodies and uses thereof 有权
标题翻译：抗IGF-1R抗体及其用途
公开(公告)号：US08168410B2
公开(公告)日：2012-05-01
申请号：US13037734
申请日：2011-03-01
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： C12P19/34 , C12N15/00 , C12N15/13 , C07H21/04 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的这些抗体及其用于预防和/或治疗某些癌症的用途的产品和/或组合物。

2. 发明申请

US20110183376A1 NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF 有权
标题翻译：新型抗IGF-1R抗体及其用途
公开(公告)号：US20110183376A1
公开(公告)日：2011-07-28
申请号：US13037734
申请日：2011-03-01
申请人： Liliane GOETSCH , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane GOETSCH , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： C12P21/04 , C07H21/04 , C12N15/63 , C12N5/10
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

3. 发明授权

US07241444B2 Anti-IGF-IR antibodies and uses thereof 有权
标题翻译：抗IGF-1R抗体及其用途
公开(公告)号：US07241444B2
公开(公告)日：2007-07-10
申请号：US10735916
申请日：2003-12-16
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： C07K16/28 , C12P21/08 , A61K39/395 , A61K39/00 , G01N33/53
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

4. 发明授权

US07914784B2 Anti-IGF-IR antibodies and uses thereof 有权
标题翻译：抗IGF-1R抗体及其用途
公开(公告)号：US07914784B2
公开(公告)日：2011-03-29
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： A61K39/395 , A61K39/00 , C12P21/08 , C07K16/18 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

5. 发明申请

US20130303734A1 NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES 审中-公开
标题翻译：新型均质抗人抗体抗体
公开(公告)号：US20130303734A1
公开(公告)日：2013-11-14
申请号：US13988913
申请日：2011-11-23
申请人： Liliane Goetsch , Nathalie Corvaia , Jean-François Haeuw , Cédric Bes , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Jean-François Haeuw , Cédric Bes , Alain Beck
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/73
摘要： The present disclosure relates to novel humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the disclosure relates to novel anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The disclosure also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The disclosure also relates to a method for the preparation of such novel humanized antibodies.
摘要翻译：本公开涉及能够抑制肿瘤生长的新型人源化抗体以及编码这种抗体的氨基酸和核酸序列。从一方面，本公开涉及能够抑制肿瘤生长的新型抗JAM-A同源人源化抗体。本公开还包括使用这样的抗体作为用于预防和/或治疗癌症的药物，以及包含这些抗体与其它抗癌化合物组合的组合物。本公开还涉及制备这种新型人源化抗体的方法。

6. 发明授权

US08071730B2 Anti-JAM-A antibodies 失效
标题翻译：抗JAM-A抗体
公开(公告)号：US08071730B2
公开(公告)日：2011-12-06
申请号：US12125726
申请日：2008-05-22
申请人： Liliane Goetsch , Nathalie Corvaia , Jean-François Haeuw , Cédric Bes
发明人： Liliane Goetsch , Nathalie Corvaia , Jean-François Haeuw , Cédric Bes
IPC分类号： C07K16/00 , C07K17/00 , C07K17/14 , C12P21/08 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/92
摘要： The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening.More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.
摘要翻译：本发明涉及能够在体外和/或体内抑制肿瘤细胞增殖并通过功能筛选获得的新型分离的抗体，衍生化合物和功能性分离的抗体片段。更具体地，本发明涉及对JAM-A蛋白特异的6F4抗体及其用于治疗癌症的用途。也涵盖由这些抗体组成的药物组合物。

7. 发明申请

US20120171114A1 ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER 审中-公开
标题翻译：抗CD151抗体及其在治疗癌症中的应用
公开(公告)号：US20120171114A1
公开(公告)日：2012-07-05
申请号：US13306839
申请日：2011-11-29
申请人： Jean-François Haeuw
发明人： Jean-François Haeuw
IPC分类号： A61K39/395 , C12N5/18 , C12N15/13 , C12N15/63 , C12N1/19 , C12P21/02 , A61K51/00 , G01N33/566 , C12N5/10 , C12N1/21 , C07K16/28 , A01K67/027
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565
摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人CD151蛋白，特别是鼠来源的单克隆抗体，它们是嵌合和人源化的新抗体，以及编码这些抗体的氨基酸和核酸序列。本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

8. 发明授权

US08697855B2 Anti-CD151 antibodies and their use in the treatment of cancer 失效
标题翻译：抗CD151抗体及其在治疗癌症中的应用
公开(公告)号：US08697855B2
公开(公告)日：2014-04-15
申请号：US13440259
申请日：2012-04-05
申请人： Jean-François Haeuw
发明人： Jean-François Haeuw
IPC分类号： C07H21/00
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/56 , C07K2317/565
摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanized, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人CD151蛋白的新型抗体，特别是嵌合和人源化的鼠来源的单克隆抗体，以及编码这些抗体的氨基酸和核酸序列。本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

9. 发明申请

US20120275997A1 CHIMERIC ANTIBODIES SPECIFIC FOR CD151 AND USE THEREOF IN THE TREATMENT OF CANCER 审中-公开
标题翻译： CD151特异性抗体特异性及其在治疗癌症中的应用
公开(公告)号：US20120275997A1
公开(公告)日：2012-11-01
申请号：US13500745
申请日：2010-10-08
申请人： Jean-François Haeuw
发明人： Jean-François Haeuw
IPC分类号： A61K39/395 , C12N15/13 , A61P35/00 , C12N5/10 , A01K67/00 , A61K51/00 , C07K16/18 , C12N15/85
CPC分类号： C07K16/2896 , C07K2317/24
摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those anitbodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人CD151蛋白的新型抗体，特别是嵌合和人源化的鼠来源的单克隆抗体，以及编码这些抗体的氨基酸和核酸序列。本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

10. 发明授权

US07408044B2 Carrier protein having an adjuvant effect 失效
标题翻译：具有佐剂作用的载体蛋白
公开(公告)号：US07408044B2
公开(公告)日：2008-08-05
申请号：US10815320
申请日：2004-04-01
申请人： Hans Binz , Thierry Baussant , Jean-François Haeuw , Thien Ngoc Nguyen
发明人： Hans Binz , Thierry Baussant , Jean-François Haeuw , Thien Ngoc Nguyen
IPC分类号： C07K1/00 , A61K39/385 , A61K39/00 , A61K39/02 , A61K45/00 , A61K39/108 , C12P21/04 , C12N15/09
CPC分类号： C07K14/005 , A61K39/385 , A61K2039/6068 , C07K14/26 , C07K2319/00 , C12N2760/18522 , Y10S530/806 , Y10S530/807 , Y10S530/825
摘要： The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.
摘要翻译：本发明涉及一种佐剂产品，其旨在在施用于宿主时改善分子的活性，其特征在于其包含至少一部分肺炎克雷伯杆菌的P40蛋白或与其中至少80％的同源性的蛋白质肺炎克雷伯杆菌的P40蛋白。本发明还涉及编码这些肽或蛋白质的核苷酸序列以及这些序列作为药物的用途。更具体地，这样的DNA序列可以用于旨在通过肌内或皮内途径免疫的组合物中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式